## Florian Kurth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4218909/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respiratory Medicine, 2022, 191, 106709.	2.9	63
2	Altered fibrin clot structure and dysregulated fibrinolysis contribute toÂthrombosis risk in severe COVID-19. Blood Advances, 2022, 6, 1074-1087.	5.2	35
3	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
4	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature Medicine, 2022, 28, 477-480.	30.7	342
5	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 2022, 185, 493-512.e25.	28.9	122
6	Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. Lancet Infectious Diseases, The, 2022, 22, 445-446.	9.1	28
7	Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. Emerging Infectious Diseases, 2022, 28, 1050-1052.	4.3	11
8	Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study. Infection, 2022, 50, 1441-1452.	4.7	10
9	<i>In Vitro</i> Screening Identifies TRPV4 and PAR1 as Targets for Endothelial Barrier Stabilization in COVIDâ€19. FASEB Journal, 2022, 36, .	0.5	1
10	Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. Journal of Clinical Immunology, 2022, 42, 1111-1129.	3.8	17
11	A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study. EClinicalMedicine, 2022, 49, 101495.	7.1	17
12	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
13	Hookworm infection in returning travellers and migrants: a 10-year case series at a German center for tropical medicine. Journal of Travel Medicine, 2021, 28, .	3.0	1
14	Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure. European Respiratory Journal, 2021, 57, 2002384.	6.7	40
15	A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. Journal of Infectious Diseases, 2021, 223, 10-14.	4.0	21
16	Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nature Biotechnology, 2021, 39, 705-716.	17.5	129
17	Breakdown in membrane asymmetry regulation leads to monocyte recognition of P. falciparum-infected red blood cells. PLoS Pathogens, 2021, 17, e1009259.	4.7	14
18	SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 629185.	4.8	42

#	Article	IF	CITATIONS
19	Ultra-fast proteomics with Scanning SWATH. Nature Biotechnology, 2021, 39, 846-854.	17.5	173
20	Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. Infection, 2021, 49, 703-714.	4.7	27
21	CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. Infection, 2021, 49, 757-762.	4.7	47
22	In vitro screening identifies TRPV4 as target for endothelial barrier stabilization in COVIDâ€19. FASEB Journal, 2021, 35, .	0.5	1
23	Estimating infectiousness throughout SARS-CoV-2 infection course. Science, 2021, 373, .	12.6	389
24	Echocardiographic Evaluation of Right Ventricular (RV) Performance over Time in COVID-19-Associated ARDS—A Prospective Observational Study. Journal of Clinical Medicine, 2021, 10, 1944.	2.4	0
25	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in Immunology, 2021, 12, 690698.	4.8	52
26	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. Clinical Microbiology and Infection, 2021, 27, 1520.e7-1520.e10.	6.0	13
27	A serum proteome signature to predict mortality in severe COVID-19 patients. Life Science Alliance, 2021, 4, e202101099.	2.8	62
28	Cross-reactive CD4 <sup>+</sup> T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science, 2021, 374, eabh1823.	12.6	221
29	A time-resolved proteomic and prognostic map of COVID-19. Cell Systems, 2021, 12, 780-794.e7.	6.2	125
30	Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021. Emerging Infectious Diseases, 2021, 27, 2169-2173.	4.3	17
31	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 1255-1265.	10.7	279
32	Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerging Infectious Diseases, 2021, 27, 2174-2178.	4.3	67
33	Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 2021, 54, 2650-2669.e14.	14.3	145
34	Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine, 2021, 40, 101099.	7.1	52
35	Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. Lancet Respiratory Medicine,the, 2021, 9, e104-e105.	10.7	65
36	Untimely TGFÎ <sup>2</sup> responses in COVID-19 limit antiviral functions of NK cells. Nature, 2021, 600, 295-301.	27.8	146

#	Article	IF	CITATIONS
37	SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell, 2021, 184, 6243-6261.e27.	28.9	277
38	A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. Cell, 2020, 183, 1058-1069.e19.	28.9	305
39	Evaluation of PEEP and prone positioning in early COVID-19 ARDS. EClinicalMedicine, 2020, 28, 100579.	7.1	49
40	Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell, 2020, 182, 1419-1440.e23.	28.9	1,162
41	RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients. Viruses, 2020, 12, 1045.	3.3	53
42	Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children. The Cochrane Library, 2020, 12, CD009568.	2.8	3
43	Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. Cell Systems, 2020, 11, 11-24.e4.	6.2	439
44	Outpatient treatment of imported uncomplicated Plasmodium falciparum malaria: results from a survey among TropNet and GeoSentinel experts for tropical medicine. Journal of Travel Medicine, 2020, 27, .	3.0	1
45	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). Infection, 2020, 48, 619-626.	4.7	79
46	COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. Nature Biotechnology, 2020, 38, 970-979.	17.5	887
47	Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria. BMJ Open, 2020, 10, e036936.	1.9	4
48	Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Frontiers in Immunology, 2020, 11, 628971.	4.8	51
49	SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature, 2020, 587, 270-274.	27.8	1,115
50	Brain magnetic resonance imaging in imported malaria. Malaria Journal, 2019, 18, 74.	2.3	8
51	Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany. Pediatric Infectious Disease Journal, 2019, 38, e295-e300.	2.0	7
52	Determinants of post-malarial anemia in African children treated with parenteral artesunate. Scientific Reports, 2019, 9, 18134.	3.3	6
53	Treatment of Severe Malaria. , 2019, , 1-12.		0
54	Chronic oral ulceration and lip swelling after a long term stay in Guatemala: A diagnostic challenge. Travel Medicine and Infectious Disease, 2018, 23, 103-104.	3.0	6

#	Article	IF	CITATIONS
55	Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses. Nature Immunology, 2018, 19, 386-396.	14.5	139
56	Chronic airflow obstruction in Tanzania – a cross-sectional study. BMC Pulmonary Medicine, 2018, 18, 11.	2.0	6
57	Severe malaria in Europe: an 8-year multi-centre observational study. Malaria Journal, 2017, 16, 57.	2.3	57
58	Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative. Eurosurveillance, 2017, 22, .	7.0	46
59	Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data. American Journal of Tropical Medicine and Hygiene, 2017, 97, 567-574.	1.4	69
60	Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated <i>Plasmodium falciparum</i> Malaria. Emerging Infectious Diseases, 2016, 22, 1381-1386.	4.3	39
61	Pyronaridine-artesunate retreatment for malaria. Lancet Infectious Diseases, The, 2016, 16, 136-137.	9.1	Ο
62	Reply to Jaureguiberry et al. Clinical Infectious Diseases, 2016, 62, 271-271.	5.8	2
63	Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study: Figure 1 Clinical Infectious Diseases, 2015, 61, 1441-1444.	5.8	38
64	Continuous Noninvasive Monitoring of Lung Recruitment during High-Frequency Oscillatory Ventilation by Electrical Impedance Measurement: An Animal Study. Neonatology, 2013, 103, 218-223.	2.0	6
65	Paediatric Formulations of Artemisinin-Combination Therapies for Treating Uncomplicated Malaria in Children. The Cochrane Library, 2012, , .	2.8	1
66	Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon. Malaria Journal, 2012, 11, 120.	2.3	34
67	Pyronaridine: a new â€~old' drug on the verge of entering the antimalarial armamentarium. Expert Review of Anti-Infective Therapy, 2011, 9, 393-396.	4.4	6
68	In vitro activity of antifungal drugs against Plasmodium falciparum field isolates. Wiener Klinische Wochenschrift, 2011, 123, 26-30.	1.9	6
69	Current status of the clinical development and implementation of paediatric artemisinin combination therapies in Sub-Saharan Africa. Wiener Klinische Wochenschrift, 2011, 123, 7-9.	1.9	8
70	High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. Malaria Journal, 2011, 10, 123.	2.3	35
71	The use of paediatric artemisinin combinations in sub-Saharan Africa: a snapshot questionnaire survey of health care personnel. Malaria Journal, 2011, 10, 365.	2.3	5
72	Pyronaridine–artesunate combination therapy for the treatment of malaria. Current Opinion in Infectious Diseases, 2011, 24, 564-569.	3.1	19

#	Article	IF	CITATIONS
73	Continuous Non-Invasive Monitoring of Tidal Volumes by Measurement of Tidal Impedance in Neonatal Piglets. PLoS ONE, 2011, 6, e21003.	2.5	9
74	Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. Wiener Klinische Wochenschrift, 2010, 122, 173-178.	1.9	22
75	Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infectious Diseases, The, 2010, 10, 125-132.	9.1	42
76	Adolescence As Risk Factor for Adverse Pregnancy Outcome in Central Africa – A Cross-Sectional Study. PLoS ONE, 2010, 5, e14367.	2.5	80
77	No Rebound of Morbidity Following Intermittent Preventive Sulfadoxineâ€Pyrimethamine Treatment of Malaria in Infants in Gabon. Journal of Infectious Diseases, 2009, 200, 1658-1661.	4.0	15
78	Treatment of malaria in Austria: hazardous for patients or physicians?. Wiener Klinische Wochenschrift, 2009, 121, 598-598.	1.9	2
79	In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malaria Journal, 2009, 8, 79.	2.3	37
80	Fixedâ€Dose Pyronaridineâ€Artesunate Combination for Treatment of Uncomplicated Falciparum Malaria in Pediatric Patients in Gabon. Journal of Infectious Diseases, 2008, 198, 911-919.	4.0	91
81	Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. Journal of Antimicrobial Chemotherapy, 2007, 60, 1091-1096.	3.0	38